These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 10451355)

  • 1. [Kinetic modeling of LDL oxidation using software (NELOP program) and validation in a population at vascular risk].
    Morena M; Vaussenat F; Maggi MF; Canaud B; Cristol JP; Descomps B
    J Soc Biol; 1999; 193(2):211-7. PubMed ID: 10451355
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation between oxidized low density lipoproteins and von Willebrand factor in chronic renal failure.
    Holvoet P; Donck J; Landeloos M; Brouwers E; Luijtens K; Arnout J; Lesaffre E; Vanrenterghem Y; Collen D
    Thromb Haemost; 1996 Nov; 76(5):663-9. PubMed ID: 8950769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oxidized low-density lipoprotein biomarkers in patients with end-stage renal failure: acute effects of hemodialysis.
    Bossola M; Tazza L; Merki E; Giungi S; Luciani G; Miller ER; Lin EB; Tortorelli A; Tsimikas S
    Blood Purif; 2007; 25(5-6):457-65. PubMed ID: 18075247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Delayed in vivo catabolism of intermediate-density lipoprotein and low-density lipoprotein in hemodialysis patients as potential cause of premature atherosclerosis.
    Ikewaki K; Schaefer JR; Frischmann ME; Okubo K; Hosoya T; Mochizuki S; Dieplinger B; Trenkwalder E; Schweer H; Kronenberg F; Koenig P; Dieplinger H
    Arterioscler Thromb Vasc Biol; 2005 Dec; 25(12):2615-22. PubMed ID: 16195474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Electronegative LDL and lipid abnormalities in patients undergoing hemodialysis and peritoneal dialysis.
    Lobo J; Santos F; Grosso D; Lima R; Barreira AL; Leite M; Mafra D; Abdalla DS
    Nephron Clin Pract; 2008; 108(4):c298-304. PubMed ID: 18434752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HDL oxidability and its protective effect against LDL oxidation in Type 2 diabetic patients.
    Sanguinetti SM; Brites FD; Fasulo V; Verona J; Elbert A; Wikinski RL; Schreier LE
    Diabetes Nutr Metab; 2001 Feb; 14(1):27-36. PubMed ID: 11345163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kinetic studies of atherogenic lipoproteins in hemodialysis patients: do they tell us more about their pathology?
    Kronenberg F; Ikewaki K; Schaefer JR; König P; Dieplinger H
    Semin Dial; 2007; 20(6):554-60. PubMed ID: 17991204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-tocopherol supplementation decreases electronegative low-density lipoprotein concentration [LDL(-)] in haemodialysis patients.
    Mafra D; Santos FR; Lobo JC; de Mattos Grosso D; Barreira AL; Velarde LG; Abdalla DS; Leite M
    Nephrol Dial Transplant; 2009 May; 24(5):1587-92. PubMed ID: 19176686
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular risk factors in non-diabetic hemodialysis patients: a comparative study.
    Tzanatos HA; Tseke PP; Pipili C; Retsa K; Skoutelis G; Grapsa E
    Ren Fail; 2009; 31(2):91-7. PubMed ID: 19212904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein alterations in hemodialysis: differences between diabetic and nondiabetic patients.
    González AI; Schreier L; Elbert A; Berg G; Beresan H; López G; Wikinski R
    Metabolism; 2003 Jan; 52(1):116-21. PubMed ID: 12524671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipoperoxidation and hemodialysis.
    Ramos R; Martínez-Castelao A
    Metabolism; 2008 Oct; 57(10):1369-74. PubMed ID: 18803940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum oxidized low-density lipoprotein is inversely correlated to telomerase activity in peripheral blood mononuclear cells of haemodialysis patients.
    Tsirpanlis G; Chatzipanagiotou S; Boufidou F; Kordinas V; Zoga M; Alevyzaki F; Stamatelou K; Frangou E; Savva L; Nicolaou C
    Nephrology (Carlton); 2006 Dec; 11(6):506-9. PubMed ID: 17199788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are metalloproteins and acute phase reactants associated with cardiovascular disease in end-stage renal failure?
    Healy H; Reith D; Morgan C; Clague A; Westhuyzen J
    Ann Clin Lab Sci; 2000 Jul; 30(3):295-304. PubMed ID: 10945571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High insulin levels and increased low-density lipoprotein oxidizability in pediatric patients with systemic lupus erythematosus.
    Posadas-Romero C; Torres-Tamayo M; Zamora-González J; Aguilar-Herrera BE; Posadas-Sánchez R; Cardoso-Saldaña G; Ladrón de Guevara G; Solis-Vallejo E; El Hafidi M
    Arthritis Rheum; 2004 Jan; 50(1):160-5. PubMed ID: 14730612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.
    van den Akker JM; Bredie SJ; Diepenveen SH; van Tits LJ; Stalenhoef AF; van Leusen R
    J Nephrol; 2003; 16(2):238-44. PubMed ID: 12768071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ceruloplasmin and acute phase protein levels are associated with cardiovascular disease in chronic dialysis patients.
    Panichi V; Taccola D; Rizza GM; Consani C; Migliori M; Filippi C; Paoletti S; Sidoti A; Borracelli D; Panicucci E; Giovannini L
    J Nephrol; 2004; 17(5):715-20. PubMed ID: 15593040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of LDL fatty acid and carotenoid concentrations and oxidative resistance of LDL in volunteers from countries with different rates of cardiovascular disease.
    Wright AJ; Southon S; Chopra M; Meyer-Wenger A; Moser U; Granado F; Olmedilla B; Corridan B; Hinninger I; Roussel AM; van den Berg H; Thurnham DI
    Br J Nutr; 2002 Jan; 87(1):21-9. PubMed ID: 11898767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma homocysteine levels and cardiovascular mortality in patients with end-stage renal disease.
    Buccianti G; Baragetti I; Bamonti F; Furiani S; Dorighet V; Patrosso C
    J Nephrol; 2004; 17(3):405-10. PubMed ID: 15365961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and cardiovascular risk factors and biomarkers in hemodialysis patients.
    Bossola M; Giungi S; Panocchia N; Vulpio C; Luciani G; Tazza L
    J Nephrol; 2008; 21(2):197-204. PubMed ID: 18446714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.